Forecast: Healthcare Expenditure on Pharmaceuticals and Medical Non-Durable Goods in Belgium

From 2013 to 2023, Belgium's healthcare expenditure on pharmaceuticals and medical non-durable goods saw a steady increase from €5.21 billion to €5.97 billion. This represents an average annual growth rate of around 1.24% over the past five years. Significant variations include a high year-on-year increase of 5.64% in 2015 and a notable decline in 2020, potentially influenced by the pandemic, with a recovery starting in 2021.

The forecast indicates continued growth, reaching an estimated €6.26 billion by 2028, with a five-year CAGR of 0.75% and an overall growth rate of 3.81%. The slower growth rate forecasted might suggest market stabilization or external regulatory impacts.

Future trends to watch for include:

• The impact of innovative pharmaceutical solutions and personalized medicine.
• Regulatory changes and their impact on pricing and expenditure.
• Shifts in population demographics, particularly aging, and their demand on healthcare services.